Cargando…

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis

BACKGROUND: Despite antiretroviral therapy, cognitive dysfunction seems to remain a major issue for people living with human immunodeficiency virus (PLWH). Previous studies showed a correlation between the width of the third ventricle (WTV) and neurocognitive disorders in PLWH. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddu-Mulindwa, Dominic, Heit, Matthias, Wagenpfeil, Gudrun, Bewarder, Moritz, Fassbender, Klaus, Behnke, Stefanie, Yilmaz, Umut, Fousse, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447481/
https://www.ncbi.nlm.nih.gov/pubmed/36081869
http://dx.doi.org/10.3389/fneur.2022.962535
_version_ 1784783864011423744
author Kaddu-Mulindwa, Dominic
Heit, Matthias
Wagenpfeil, Gudrun
Bewarder, Moritz
Fassbender, Klaus
Behnke, Stefanie
Yilmaz, Umut
Fousse, Mathias
author_facet Kaddu-Mulindwa, Dominic
Heit, Matthias
Wagenpfeil, Gudrun
Bewarder, Moritz
Fassbender, Klaus
Behnke, Stefanie
Yilmaz, Umut
Fousse, Mathias
author_sort Kaddu-Mulindwa, Dominic
collection PubMed
description BACKGROUND: Despite antiretroviral therapy, cognitive dysfunction seems to remain a major issue for people living with human immunodeficiency virus (PLWH). Previous studies showed a correlation between the width of the third ventricle (WTV) and neurocognitive disorders in PLWH. PATIENTS AND METHODS: We investigated prevalence and correlation of neuropsychological disorders using WTV as a brain atrophy marker examined by transcranial sonography and MRI in PLWH and healthy age- and gender-matched controls. We used Becks Depression Inventory (BDI) for depression screening, the questionnaires Fatigue Severity Scale (FSS) for fatigue and Short-Form-36 (SF36) for quality of life (QoL) evaluation and Consortium to establish a registry for Alzheimer's disease (CERAD-PLUS) as neuropsychological test battery. RESULTS: 52 PLWH (47 males) and 28 non-infected controls (23 males) with a median age of 52 years (24–78 years) and 51 years (22–79) were analyzed. WTV correlated significantly with age (p < 0.01) but showed no significantly difference in PLWH (median = 3.4 mm) compared to healthy controls (median = 2.8 mm) (p = 0.085). PLWH had both significantly higher BDI-Scores (p = 0.005) and FSS-Scores (p = 0.012). Controls reported higher QoL (SF-36) with significant differences in most items. However, the overall cognitive performance (CERAD total score) showed no significant difference. The WTV of all subjects correlated with neurocognitive performance measured as CERAD total score (p = 0.009) and trail making tests A (p < 0.001) and B (p = 0.018). There was no correlation between the scores of BDI, FSS, SF-36, and CERAD-PLUS items and WTV. CONCLUSION: WTV is considered as a predictor of cognitive deficits in neurodegenerative diseases. Nevertheless, we found no significant difference in WTV or overall cognitive performance between PLWH and controls. PLWH suffer more often from depression and fatigue and report reduced QoL when compared to healthy controls.
format Online
Article
Text
id pubmed-9447481
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94474812022-09-07 Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis Kaddu-Mulindwa, Dominic Heit, Matthias Wagenpfeil, Gudrun Bewarder, Moritz Fassbender, Klaus Behnke, Stefanie Yilmaz, Umut Fousse, Mathias Front Neurol Neurology BACKGROUND: Despite antiretroviral therapy, cognitive dysfunction seems to remain a major issue for people living with human immunodeficiency virus (PLWH). Previous studies showed a correlation between the width of the third ventricle (WTV) and neurocognitive disorders in PLWH. PATIENTS AND METHODS: We investigated prevalence and correlation of neuropsychological disorders using WTV as a brain atrophy marker examined by transcranial sonography and MRI in PLWH and healthy age- and gender-matched controls. We used Becks Depression Inventory (BDI) for depression screening, the questionnaires Fatigue Severity Scale (FSS) for fatigue and Short-Form-36 (SF36) for quality of life (QoL) evaluation and Consortium to establish a registry for Alzheimer's disease (CERAD-PLUS) as neuropsychological test battery. RESULTS: 52 PLWH (47 males) and 28 non-infected controls (23 males) with a median age of 52 years (24–78 years) and 51 years (22–79) were analyzed. WTV correlated significantly with age (p < 0.01) but showed no significantly difference in PLWH (median = 3.4 mm) compared to healthy controls (median = 2.8 mm) (p = 0.085). PLWH had both significantly higher BDI-Scores (p = 0.005) and FSS-Scores (p = 0.012). Controls reported higher QoL (SF-36) with significant differences in most items. However, the overall cognitive performance (CERAD total score) showed no significant difference. The WTV of all subjects correlated with neurocognitive performance measured as CERAD total score (p = 0.009) and trail making tests A (p < 0.001) and B (p = 0.018). There was no correlation between the scores of BDI, FSS, SF-36, and CERAD-PLUS items and WTV. CONCLUSION: WTV is considered as a predictor of cognitive deficits in neurodegenerative diseases. Nevertheless, we found no significant difference in WTV or overall cognitive performance between PLWH and controls. PLWH suffer more often from depression and fatigue and report reduced QoL when compared to healthy controls. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9447481/ /pubmed/36081869 http://dx.doi.org/10.3389/fneur.2022.962535 Text en Copyright © 2022 Kaddu-Mulindwa, Heit, Wagenpfeil, Bewarder, Fassbender, Behnke, Yilmaz and Fousse. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Kaddu-Mulindwa, Dominic
Heit, Matthias
Wagenpfeil, Gudrun
Bewarder, Moritz
Fassbender, Klaus
Behnke, Stefanie
Yilmaz, Umut
Fousse, Mathias
Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title_full Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title_fullStr Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title_full_unstemmed Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title_short Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis
title_sort fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in plwh treated with modern art: a prospective analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447481/
https://www.ncbi.nlm.nih.gov/pubmed/36081869
http://dx.doi.org/10.3389/fneur.2022.962535
work_keys_str_mv AT kaddumulindwadominic fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT heitmatthias fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT wagenpfeilgudrun fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT bewardermoritz fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT fassbenderklaus fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT behnkestefanie fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT yilmazumut fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis
AT foussemathias fewerneurocognitivedeficitsandlessbrainatrophybythirdventriclemeasurementinplwhtreatedwithmodernartaprospectiveanalysis